XML 17 R6.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Cash Flows - Unaudited - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash flows from operating activities:    
Net loss before noncontrolling interest $ (21,525) $ (18,983)
Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:    
Depreciation expense 67 69
Loss from G42 Promissory Note early redemption 313 0
Non-cash interest income (100) (200)
Interest expense 0 9
Share-based compensation expense 1,175 981
Change in fair value of investments (3,044) 2,998
Impairment of investments in Anteris Bio, Inc. 4,245 0
Change in fair value of warrants, related party (406) (221)
Changes in assets and liabilities:    
Accounts receivable 173 0
Prepaid expenses and other assets 665 853
Accounts payable and accrued expenses 2,270 (1,417)
Contract liabilities 0 6,769
Net cash used in operating activities (16,167) (9,142)
Cash flows from investing activities:    
Purchases of property and equipment 0 (21)
Net cash used in investing activities 0 (21)
Cash flows from financing activities:    
Proceeds from G42 Promissory Note early redemption related to sale of Class A common stock to collaboration partner 12,030 0
Proceeds from sale of Class A common stock to collaboration partner, net of offering costs 0 5,040
Proceeds from sale of Class A common stock and warrants, net of offering costs 0 5,746
Proceeds from debt issuance 566 776
Repayment of notes payable (317) (475)
Net cash provided by financing activities 12,279 11,087
Net (decrease) increase in cash and cash equivalents (3,888) 1,924
Total cash and cash equivalents, beginning of period 12,126 13,415
Total cash and cash equivalents, end of period 8,238 15,339
Non-cash activities:    
Change in redemption value of noncontrolling interest (1,104) 3,809
Notes receivable recorded at fair value from collaboration partner 0 11,891
Notes receivable for common stock from CinRx purchase agreement 0 11,891
CinRx    
Non-cash activities:    
Notes receivable recorded at fair value from collaboration partner 0 4,000
Notes receivable for common stock from CinRx purchase agreement $ 0 $ 4,000